Catalyst Pharma (CPRX) Closes $6M Direct Offering
Tweet Send to a FriendGet Alerts CPRX Hot Sheet
Up)
Trade CPRX Now!
Catalyst Pharmaceutical Partners, Inc. (Nasdaq: CPRX) announced today that it has closed its previously announced offering of (i) 4.0 million shares of the Company's common stock, and (ii) warrants to purchase an aggregate of 1.2 million shares of the Company's common stock, in a registered direct public offering.
The aggregate offering price for each share and corresponding warrant was $1.50, resulting in gross proceeds of $6 million.
The common stock purchase warrants have a five-year term and an exercise price of $2.08 per share.
Roth Capital Partners acted as the exclusive placement agent for the transaction.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The aggregate offering price for each share and corresponding warrant was $1.50, resulting in gross proceeds of $6 million.
The common stock purchase warrants have a five-year term and an exercise price of $2.08 per share.
Roth Capital Partners acted as the exclusive placement agent for the transaction.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Baltic Trading (BALT) to Sell 5.58M Common at $3.60/Share
- Cleantech Solutions (CLNT) Becomes Certified Supplier to Sinopec and CPNC
- Telsa (TSLA) Repays DOE Loan Facility
Create E-mail Alert Related Categories
Corporate News, Equity OfferingsRelated Entities
Roth Capital
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
